se of doxycycline in tuberculosis (TB) patients
- Conditions
- Health Condition 1: A150- Tuberculosis of lung
- Registration Number
- CTRI/2024/01/061473
- Lead Sponsor
- Jawaharlal Institute of Postgraduate Medical Education & Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Females (who have completed their family or undergone sterilization)and males- who were newly diagnosed clinically and microbiologically confirmed drug sensitive pulmonary tuberculosis patients who have been receiving anti-tubercular
therapy for = 7days or about to start standard
ATT with chest X-Ray demonstrating pulmonary
cavity/cavities
Patients with extra pulmonary tuberculosis, previous history of pulmonary TB, HIV coinfections, severe preexisting lung diseases
(such as fibrosis, COPD, lung cancer, bronchiectasis) and autoimmune diseases
Patients with ALT/ AST >3 times upper limit of
normal
Patients with Creatinine > 2 times upper limit of
normal
Patient on antiepileptic therapy
Known hypersensitivity to tetracyclines
Patients who have taken tetracycline in the past
30 days preceding the dosing of study drug
Patient who participated in other clinical trials in past 180 days
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Matrix metalloproteinase 1Timepoint: Baseline, 1month
- Secondary Outcome Measures
Name Time Method Cumulative lung cavity volume, wall thickness, lobe involvement, CT severity score using Low dose Chest CTTimepoint: Baseline, 6months;Matrix Metalloproteinases 3,8Timepoint: Baseline, 1month;Pulmonary function testTimepoint: 6 months;Quality of life using St George Respiratory QuestionnaireTimepoint: Baseline, 6months;Sputum microscopy/ cultureTimepoint: Baseline, end of intensive therapy, end of tuberculosis therapy